BillionToOne is at the forefront of defining disease using proprietary Quantitative Counting Templates (QCTs™) powering their smNGS platform to measure sparse disease-causing DNA fragments at the single base-pair level. Their technology enables quantifying minute variations in cell-free DNA, improving prenatal screening, liquid biopsy, and beyond. They offer products like Unity Complete® (a non-invasive prenatal test) and Northstar Select® and Northstar Response® (pan-cancer liquid biopsy tests).